Literature DB >> 15271999

Interleukin-13 stimulates the transcription of the human alpha2(I) collagen gene in human dermal fibroblasts.

Masatoshi Jinnin1, Hironobu Ihn, Kenichi Yamane, Kunihiko Tamaki.   

Abstract

Interleukin (IL)-13 is a novel lymphokine produced by activated Type 2 helper cells. In this study, we examined the target genes of IL-13 by the cDNA microarray analysis in human dermal fibroblasts. We focused on the human alpha2(I) collagen gene, which was one of the IL-13-induced genes by the microarray analysis. IL-13 induced type I collagen protein as well as mRNA in a dose-dependent manner. Actinomycin D, an RNA synthesis inhibitor, significantly blocked the IL-13-mediated up-regulation of alpha2(I) collagen mRNA expression, whereas cycloheximide, a protein synthesis inhibitor, did not block this up-regulation. In addition, IL-13 treatment induced the promoter activity of alpha2(I) collagen by nuclear run-on transcription assay and chloramphenicol acetyltransferase assay. IL-13-mediated transcriptional activation of alpha2(I) collagen gene or type I collagen protein up-regulation was inhibited by the treatment of fibroblasts with a selective phosphoinositide 3-kinase (PI3K) inhibitor, LY294002, or STAT6 antisense oligonucleotide, but not by PD98059, a specific inhibitor of MEK/ERK, or SB202190 or SB203580, specific inhibitors of p38 MAPK; IL-13 induced the phosphorylation of PI3K p85 regulatory subunit and STAT6. These results suggest that IL-13 may play a role in the regulation of extracellular matrix and indicate the possible therapeutic value of the blockade of IL-13 signaling pathways via PI3K and STAT6 in fibrosis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15271999     DOI: 10.1074/jbc.M406951200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  26 in total

1.  Collagenous sprue: a case report and literature review.

Authors:  Zuoliang Xiao; Vijaya M Dasari; Donald F Kirby; Mary Bronner; Thomas P Plesec; Bret A Lashner
Journal:  Gastroenterol Hepatol (N Y)       Date:  2009-06

Review 2.  Recent advances on pathogenesis and therapies in systemic sclerosis.

Authors:  Norihito Yazawa; Manabu Fujimoto; Kunihiko Tamaki
Journal:  Clin Rev Allergy Immunol       Date:  2007-10       Impact factor: 8.667

Review 3.  The pathogenesis of systemic sclerosis revisited.

Authors:  Matthias Geyer; Ulf Müller-Ladner
Journal:  Clin Rev Allergy Immunol       Date:  2011-04       Impact factor: 8.667

4.  A review of the foreign-body response to subcutaneously-implanted devices: the role of macrophages and cytokines in biofouling and fibrosis.

Authors:  W Kenneth Ward
Journal:  J Diabetes Sci Technol       Date:  2008-09

Review 5.  Fibrosis--a lethal component of systemic sclerosis.

Authors:  Yuen Yee Ho; David Lagares; Andrew M Tager; Mohit Kapoor
Journal:  Nat Rev Rheumatol       Date:  2014-04-22       Impact factor: 20.543

Review 6.  Pathogenesis of systemic sclerosis-current concept and emerging treatments.

Authors:  Masutaka Furue; Chikage Mitoma; Hiroki Mitoma; Gaku Tsuji; Takahito Chiba; Takeshi Nakahara; Hiroshi Uchi; Takafumi Kadono
Journal:  Immunol Res       Date:  2017-08       Impact factor: 2.829

Review 7.  Scleroderma, fibroblasts, signaling, and excessive extracellular matrix.

Authors:  Hironobu Ihn
Journal:  Curr Rheumatol Rep       Date:  2005-04       Impact factor: 4.592

Review 8.  NADPH oxidase enzymes in skin fibrosis: molecular targets and therapeutic agents.

Authors:  Olubukola Babalola; Andrew Mamalis; Hadar Lev-Tov; Jared Jagdeo
Journal:  Arch Dermatol Res       Date:  2013-10-24       Impact factor: 3.017

9.  Interleukin-13-producing CD8+ T cells mediate dermal fibrosis in patients with systemic sclerosis.

Authors:  Patrizia Fuschiotti; Adriana T Larregina; Johnan Ho; Carol Feghali-Bostwick; Thomas A Medsger
Journal:  Arthritis Rheum       Date:  2013-01

Review 10.  The IL-4/IL-13 axis in skin fibrosis and scarring: mechanistic concepts and therapeutic targets.

Authors:  Julie K Nguyen; Evan Austin; Alisen Huang; Andrew Mamalis; Jared Jagdeo
Journal:  Arch Dermatol Res       Date:  2019-09-06       Impact factor: 3.017

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.